Allspring Global Investments
ELVN icon

Allspring Global Investments’s Enliven Therapeutics ELVN Stock Holding History

Allspring Global Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-566
Closed -$7.73K – 2381
2023
Q3 		$7.73K Buy
+566
New +$9.53K ﹤0.01% 2638

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allspring Global Investments's ELVN Position: Q4 2023 in Review

Allspring Global Investments sold out of Enliven Therapeutics (ELVN) in Q4 2023, closing a stake of 566 shares — an estimated $7.73K sold.

Allspring Global Investments first reported a position in ELVN in Q3 2023 and held it in 1 quarter. The position peaked at $7.73K in Q3 2023. 62 funds tracked by Wall St. Rank hold ELVN as of Q4 2023.

  • Allspring Global Investments reported no remaining Enliven Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 566 Enliven Therapeutics shares in Q4 2023, an estimated $7.73K.
  • Allspring Global Investments first reported a position in Enliven Therapeutics in Q3 2023 and held it in 1 quarter.
  • Allspring Global Investments's Enliven Therapeutics position peaked at $7.73K in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.